dm+d

34022811000001105

New Medicines

NinlaroMultiple myeloma (MM) - maintenance after autologous stem cell transplant

Information

Ninlaro
Licence extension / variation
Takeda
Millennium Pharmaceuticals

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Filing withdrawn

Category

Proteasome inhibitor
The UK incidence of MM is 7.7 per 100,000 people and prevalence is about 16 in 100,000 people.
Multiple myeloma (MM) - maintenance after autologous stem cell transplant
Oral

Further information

Yes

Evidence based evaluations

NinlaroMultiple myeloma (MM) - maintenance in newly diagnosed patients not treated with stem cell transplant

Information

Ninlaro
Licence extension / variation
Takeda
Millennium Pharmaceuticals

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Proteasome inhibitor
UK incidence of MM is 7.7 per 100,000 people and prevalence is about 16 in 100,000 people.
Multiple myeloma (MM) - maintenance in newly diagnosed patients not treated with stem cell transplant
Oral

Further information

Yes

Evidence based evaluations